Estados financieros detallados de MAIA Biotechnology, Inc. (MAIA): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $1.40, MAIA presenta beneficios negativos (P/E no significativo) y un ROE del -211.15%. La capitalización bursátil es de $85M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| I+D | $1.9M | $1.4M | $3.5M | $8.9M | $11.1M | $10.0M | $14.55B |
| Generales y Administrativos | $5.0M | $5.6M | $4.3M | $6.1M | $9.1M | $6.9M | $9.72B |
| Gastos Operativos | $6.9M | $7.0M | $7.8M | $16.2M | $20.2M | $17.0M | $24.3M |
| Beneficio Operativo | -$6.9M | -$7.0M | -$7.8M | -$16.2M | -$20.2M | -$17.0M | -$24.3M |
| EBITDA | 0 | 0 | -$11.8M | -$15.8M | -$19.8M | -$23.3M | -$22.4M |
| Gastos por Intereses | | $31547 | $827539 | $6967 | 0 | $57 | 0 |
| Beneficio Antes de Impuestos | -$6.9M | -$7.0M | -$12.6M | -$15.8M | -$19.8M | -$23.3M | -$22.4M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$6.5M | -$6.6M | -$12.5M | -$15.8M | -$19.8M | -$23.3M | -$22.4M |
| BPA | $-0.61 | $-0.62 | $-1.18 | $-1.70 | $-1.49 | $-1.05 | $-0.70 |
| BPA Diluido | $-0.61 | $-0.62 | $-1.18 | $-1.70 | $-1.49 | $-1.05 | $-0.70 |
| Acciones en Circulación (Diluidas) | $10.6M | $10.6M | $10.6M | $9.3M | $13.3M | $22.2M | $32.1M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | 0 |
| Beneficio Operativo | -$9.4M | -$4.3M | -$6.9M | -$8.3M |
| EBITDA | $457737 | -$3.6M | -$6.4M | -$7.6M |
| Beneficio Neto | -$8.9M | -$3.6M | -$6.4M | -$7.9M |
| BPA | $-0.27 | $-0.09 | $-0.14 | $-0.13 |
| BPA Diluido | $-0.27 | $-0.09 | $-0.14 | $-0.13 |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $1.7M | $663457 | $10.6M | $11.0M | $7.2M | $9.6M | $8.66B |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | 0 | $43666 | $302789 | $144680 | $77347 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $1.7M | $746505 | $10.7M | $11.8M | $7.6M | $10.2M | $9.7M |
| Inmovilizado Material | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $1.7M | $746505 | $11.3M | $12.0M | $7.6M | $10.2M | $9.7M |
| Cuentas por Pagar | $169188 | $154886 | $960401 | $1.2M | $1.6M | $1.5M | $2.0M |
| Deuda a Corto | $25000 | $31953 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $374565 | $1.7M | $2.1M | $3.3M | $4.9M | $3.8M | $5.8M |
| Deuda a Largo | $9172 | $431801 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $409737 | $2.4M | $2.1M | $3.5M | $7.1M | $6.5M | $7.3M |
| Reservas | -$9.3M | -$15.9M | -$28.4M | -$44.2M | -$64.0M | -$87.2M | -$109.6M |
| Patrimonio Neto | -$172867 | -$3.3M | $9.2M | $8.5M | $477511 | $3.6M | $2.4M |
| Deuda Total | $34172 | $463754 | 0 | 0 | 0 | 0 | 0 |
| Deuda Neta | -$1.7M | -$199703 | -$10.6M | -$11.0M | -$7.2M | -$9.6M | -$8.66B |
| Capital Circulante | $1.4M | -$947239 | $8.5M | $8.5M | $2.6M | $6.3M | $3.9M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $10.9M | $8.7M | $34.4M | $27.6M |
| Activos Totales | $11.8M | $9.7M | $35.3M | $28.2M |
| Pasivos Totales | $11.7M | $7.3M | $7.6M | $7.6M |
| Patrimonio Neto | $41670 | $2.4M | $27.8M | $20.7M |
| Deuda Total | 0 | 0 | 0 | 0 |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$6.5M | -$7.0M | -$12.6M | -$15.8M | -$19.8M | -$23.3M | -$22.4M |
| Amortizaciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Compensación en Acciones | 0 | $3.9M | $2.7M | $2.3M | $3.1M | $1.9M | $2.6M |
| Cambio en Capital Circulante | $269457 | $1.3M | $1.1M | $352782 | $3.1M | -$1.2M | $1.5M |
| Flujo de Caja Operativo | -$1.6M | -$1.8M | -$4.1M | -$12.1M | -$13.1M | -$15.7M | -$18.8M |
| Inversiones (CapEx) | $2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adquisiciones | $187556 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$1.6M | -$1.8M | -$4.1M | -$12.1M | -$13.1M | -$15.7M | -$18.8M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$3.5M | -$7.0M | -$5.3M | -$6.8M |
| Inversiones (CapEx) | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$3.5M | -$7.0M | -$5.3M | -$6.8M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $646900 | $810796 | $650024 | $723915 |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Beneficio Neto (anual) | | -2.2% | -88.4% | -26.1% | -25.4% | -17.6% | +3.7% |
| Crecimiento BPA (anual) | | -1.6% | -90.3% | -44.1% | +12.4% | +29.5% | +33.3% |
| Cambio en Acciones (anual) | | +0.0% | -0.0% | -12.8% | +43.0% | +67.4% | +44.7% |
| Crecimiento FCF (anual) | | -17.8% | -123.6% | -193.4% | -8.1% | -20.1% | -20.0% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-0.15 | $-0.17 | $-0.39 | $-1.30 | $-0.99 | $-0.71 | $-0.59 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $10.6M | $10.6M | $10.6M | $9.3M | $13.3M | $22.2M | $32.1M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -211.15% |
| Rentabilidad sobre capital invertido | -131.68% |
| Rentabilidad sobre activos | -95.06% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.00 |
| Ratio corriente | 4.51 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -19.57 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -7.31 | -7.19 | -3.78 | -2.06 | -0.79 | -1.89 | -2.19 |
| P/VC | -274.41 | -14.22 | 5.17 | 3.83 | 32.49 | 12.09 | 20.68 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |